510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

Trabecular Metal Knee System Augments

Submitter Name:	Zimmer Trabecular Metal Technology, Inc.
Submitter Address:	80 Commerce Drive Allendale, New Jersey 07401-1600
Contact Person(s):	Marci Halevi
Phone Number:	(201) 818-1800 ext 507
Fax Number:	(973) 829-0825
Date Prepared:	November 28, 2005
Device Trade Name:	Trabecular Metal Tibial Cone Augments and Trabecular Metal Femoral Cone Augments
Device Common Name:	Knee System Augments
Classification Name:	Prosthesis, knee, patello/femorotibial, semi-constrained, uncemented, porous, coated, polymer/metal/polymer

Substantial Equivalence:	**The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence found in the Federal Food, Drug and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E under which a device can be marketed without premarket approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.**
Predicate Devices:	Trabecular Metal Tibial Cone Augments (K031962) Trabecular Metal Femoral Cone Augments (K051756), Trabecular Metal Knee System Augments (K040487) NexGen Knee System Uncemented Components (K031462).

510(K) Summary of Safety and Effectiveness - Continued...

Device Description:

The ***Trabecular Metal Tibial Cone Augments and Trabecular Metal Femoral Cone Augments*** are manufactured to be compatible for use with Zimmer's *NexGen Complete Knee Solution - Rotating Hinge Knee (RHK) System* and Zimmer's *NexGen Complete Knee Solution - Legacy Knee Constrained Condylar Knee (LCCK) System.* When used with the *RHK System,* the Trabecular Metal Cone Augments are for cemented use only. When used with the LCCK *System,* the Trabecular Metal Augments are for either cementless or cemented use.

Intended Use:

Trabecular Metal Tibial Cone Augments and *Trabecular Metal Femoral Cone Augments* are intended for use where severe degeneration, trauma, or other pathology of the knee joint indicates total knee arthroplasty. When used with the *NexGen Complete Knee Solution – Rotating Hinge Knee (RHK) System,* the *Trabecular Metal Tibial Cone Augments* and *Trabecular Metal Femoral Cone Augments* are for cemented use only. When used with the *NexGen Complete Knee Solution – Legacy Constrained Condylar Knee System,* the *Trabecular Metal Tibial Cone Augments* and *Trabecular Metal Femoral Cone Augments* are for cementless or cemented use.

Performance Data:

The predicate and subject devices are identical; performance characteristics therefore remain as documented in the predicate submission (K031962 and K051756).

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB 27 2006

Zimmer Trabecular Metal Technology, Inc.
c/o Ms. Marci Halevi
Manager of Regulatory Affairs
80 Commerce Drive
Allendale, New Jersey 07401-1600

Re: K053340
Trade/Device Name: Trabecular Metal Tibial Cone Augments and Trabecular Metal Femoral Cone Augments
Regulation Number: 21 CFR 888.3565 and 21 CFR 888.3560
Regulation Name: Knee joint patellofemorotibial metal/polymer porous-coated uncemented prosthesis, Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis
Regulatory Class: II
Product Code: MBH, JWH
Dated: November 30, 2005
Received: December 1, 2005

Dear Ms. Halevi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

for Mark N. Melkerson, M.S.
Acting Director
Division of General, Restorative and
Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K053340

Device Name: ***Trabecular Metal Tibial Cone Augments*** **and** ***Trabecular Metal Femoral Cone Augments***

Indications for Use:

Trabecular Metal Tibial Cone Augments and *Trabecular Metal Femoral Cone Augments* are intended for use where severe degeneration, trauma, or other pathology of the knee joint indicates total knee arthroplasty. When used with the *NexGen Complete Knee Solution – Rotating Hinge Knee (RHK) System,* the *Trabecular Metal Tibial Cone Augments* and *Trabecular Metal Femoral Cone Augments* are for cemented use only. When used with the *NexGen Complete Knee Solution – Legacy Constrained Condylar Knee System,* the *Trabecular Metal Tibial Cone Augments* and *Trabecular Metal Femoral Cone Augments* are for cementless or cemented use.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

Page __ of ___

*(Posted November 13, 200*5**10(k) Number**_____